Guía de Práctica Clínica sobre la Prevención Primaria y Secundaria del Ictus.

V. resumida | Info. pacientes | Consulta rápida

  1. Introducción
  2. Alcance y objetivos
  3. Metodología
  4. Riesgo vascular
  5. Clasificación etiológica del ictus
  6. Prevención primaria del ictus
  7. Prevención secundaria del ictus
  8. Difusión e implementación
  9. Recomendaciones de investigación futura
  10. Anexos
  11. Bibliografía
  12. Listado completo de tablas y figuras

Abre nueva ventana: Bibliografía en versión pdf
Descargar GPC sobre Prevención del Ictus (2,46 Mb)

Bibliografía

1. World Health Organization, Preventing chronic diseases: a vital investment; 2005 [consultado el 19 de Marzo de 2008]. Disponible en: http://www.who.int/chp/chronic_disease_report/full_report.pdf Abre nueva ventana

2. The European Stroke Initiative Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for Stroke Management. Update 2003. Cerebrovasc Dis. 2003;16:311-337.

3. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6(2):182-7.

4. Horton R. Chronic diseases: the case for urgent global action. Lancet. 2007;370 (9603):1881-2.

5. Stroke-prevention is better than cure. Lancet. 2007;369:247.

6. Wolfe CD, Giroud M, Kolomisky-Rabas P, Dundas R, Lemesle M, Heuschmann P, et al. Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke. 2000;31(9):2074-9.

7. López-Pousa S, Vilalta J, Llinás J. Incidencia de la enfermedad vascular cerebral en España: estudio en un área rural de Girona. Rev Neurol. 1995;23:1074-80.

8. Caicoya M, Rodríguez T, Lasheras C, Cuello R, Corrales C, Blázquez B. Incidencia del accidente cerebrovascular en Asturias: 1990-1991. Rev Neurol. 1996;24:806-11.

9. Díaz-Guzmán J, Egido J, Abilleira S, Barberá G, Gabriel R, en representación del grupo Proyecto Ictus (GEECV) de la Sociedad Española de Neurología. Incidencia del ictus en España: datos preliminares crudos del estudio Iberictus. Neurología. 2007;22(9):605.

10. Aymerich N, Zandio B, Martín M, Muruzábal J, Delgado G, Gállego J, et al. Incidencia de ictus y mortalidad precoz en la comarca de Pamplona. Neurología. 2007;22(9):603.

11. Marrugat J, Arboix A, García-Eroles L, Salas T, Vila J, Castell C, et al. The estimated incidence and case fatality rate of ischemic and hemorrhagic cerebrovascular disease in 2002 in Catalonia. Rev Esp Cardiol. 2007;60(6):573-80.

12. Sempere AP, Duarte J, Cabezas C, Clavería LC. Incidence of transient ischemic attacks and minor ischemic strokes in Segovia, Spain. Stroke. 1996;27:667-71.

13. Encuesta Nacional de Morbilidad Hospitalaria. INE 2005. [consultado el 19 de Marzo de 2008]. Disponible en: http://www.ine.es. Abre nueva ventana

14. Ministerio de Sanidad y Consumo. Estrategia en Cardiopatía Isquémica del Sistema Nacional de Salud. Madrid (España): Ministerio de Sanidad y Consumo; Centro de Publicaciones; 2006.

15. [Informe MSC Desigualdades 2006] Desigualdades de mortalidad en las comunidades autónomas entre 1981 y 2002. Observatorio de Salud de la Mujer. Dirección General de la Agencia de Calidad del Sistema Nacional de Salud. Secretaría General de Sanidad. Ministerio de Sanidad y Consumo; 2006.

16. López-Abente G, Ramis R, Pollán M, Aragonés N, Pérez-Gómez B, Gómez- Barroso D, et al. Atlas municipal de mortalidad por cáncer en España, 1989-1998. Madrid (España): Instituto de Salud Carlos III; 2006.

17. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de práctica clínica en el SNS: I+CS Nº 2006/0I.

18. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14. Suppl 2:S1-113.

19. Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension; analysis based on 11 major randomized trials. Blood Press. 2001;10:190-2.

20. Masana Ll. ¿Qué tablas de riesgo cardiovascular debemos utilizar? Rev Esp Cardiol 2007;60(7):690-2.

21. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9.

22. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: A statement for health professionals. Circulation 1991;83:356-62.

23. Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordon F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.

24. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.

25. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752-9.

26. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care:The Framingham Heart Study. Circulation. 2008;117:743-53.

27. Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study. J Epidemiol Community Health. 2007;61:40-7.

28. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.

29. Comín E, Solanas P, Cabezas C, Subirana I, Ramos R, et al. Rendimiento de la estimación del riesgo cardiovascular en España utilizando distintas funciones. Rev Esp Cardiol. 2007;60:693-702.

30. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol. 2007;60:476-85.

31. Buitrago F, Cañón L, Díaz N, Cruces E, Bravo B, Pérez I. Comparación entre la tabla del SCORE y la función Framingham-REGICOR en la estimación del riesgo cardiovascular en una población urbana seguida durante 10 años. Med Clin (Barc). 2006;127:368-73.

32. Fornasini M, Brotons C, Sellarès J, Martinez M, Galán ML, Sáenz I, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Fam Pract. 2005;23:28-33.

33. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, et al. Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy. The CHECK-UP Study: A Randomized Controlled Trial. Arch Intern Med. 2007;167(21):2296-303.

34. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19(6):596-604.

35. Llibre blanc. Consens sobre les activitats preventives a l’edat adulta dins l’atenció primària. Barcelona (España): Direcció General de Salut Pública. Departament de Salud. Generalitat de Cataluña; 2005.

36. Díez Tejedor E, Fuentes B, Gil Núñez AC, Gil Peralta A, Matías Guiu J, por el comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN. Guía para el tratamiento preventivo de la isquemia cerebral. En: Díez Tejedor, editor. Guía para el diagnostico y tratamiento del ictus. Guías oficiales de la Sociedad Española de Neurología. Barcelona: Prous Science; 2006:133-183.

37. Wolf PA, D’Agostino RB, O’Neal MA, Sytkowski P, Kase CS, Belanger AJ, et al. Secular trends in stroke incidence and mortality: the Framingham Study. Stroke. 1992;23:1551-5.

38. Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-80.

39. Warlow C, Sudlow C, Dennis M. Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211-24.

40. Villar F, Banegas JR, de Mata J, Rodríguez F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe Sociedad Española de Arteriosclerosis. Madrid: Visto Bueno Equipo Creativo; 2007.

41. Marrugat J, Sala J, Aboal J. Epidemiology of cardiovascular disease in women. Rev Español Cardiol. 2006;59(3):264-74.

42. Prencipe M, Ferretti C, Casini AR, Santini M, Giubilei F, Culasso F. Stroke, disability and dementia: results of a population survey. Stroke. 1997;28:5316.

43. Morin Martin M, González-Santiago R, Gil Núñez AC, Vivancos-Mora J. El ictus en la mujer. Epidemiología hospitalaria en España. Rev Neurol. 2003;37:701-5.

44. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259-68.

45. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-21.

46. Gorelick PB. Cerebrovascular disease in African Americans. Stroke. 1998;29: 2656-64.

47. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: the National Longitudinal Mortality Study. Stroke. 1994;25:2120-5.

48. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, et al. Stroke incidence and survival among middle-aged adults: 9-year followup of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-43.

49. Beltrán-Blasco I, Medrano V, Sánchez-Pérez RM, Moltó-Jordà JM, Matías-Guiu J. Diferencias entre pacientes con ictus isquémico españoles frente a centro y nordeuropeos: un estudio de casos y controles. Rev Neurol. 2005;40:193-8.

50. Saunders E, Ofili E. Effectiveness and Risks of Antiplatelet Therapy: Race and Ethnicity Considerations. Cardiol Rev. 2008;16(2):82-8.

51. Park IU, Taylor AL. Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review. Ann Fam Med. 2007;5:444-52.

52. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke: the Framingham Study. Stroke. 1993;24:1366-71.

53. Liao D, Myers R, Hunt S, Shahar E, Paton C, Burke G, et al. Familial history of stroke and stroke risk: the Family Heart Study. Stroke. 1997;28:1908-12.

54. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke. 2004;35(1):212-27.

55. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.

56. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke. 2006;37(8):2181-8.

57. Diet, nutrition and the prevention of chronic diseases:Report of a jointWHO/FAO expert consultation. Geneva (Switzerland): World Health Organization; 2003. WHO Technical Report Series No. 916.

58. Klatsky AL. Alcohol and Stroke. An Epidemiological Labyrinth. Stroke. 2005;36(9):1835-36.

59. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease:meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999 Dec 11;319(7224):1523-8.

60. Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and coronary heart disease: a meta-analysis. Addiction. 2000;95(10):1505-23.

61. Cleophas TJ. Wine, beer and spirits and the risk of myocardial infarction: a systematic review. Biomed Pharmacother. 1999;53(9):417-23.

62. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA. 2003;289(5):579-88.

63. Elkind MSV, Sciacca R, Boden-Albala B, Rundek T, Paik MC, Sacco RL. Moderate Alcohol Consumption Reduces Risk of Ischemic Stroke-the Northern Manhattan Study. Stroke. 2006;37(1):13-9.

64. Mukamal KJ, Chung HJ, Jenny NS, et al. Alcohol Use and Risk of Ischemic Stroke Among Older Adults the Cardiovascular Health Study. Stroke. 2005;36(9):1830-4.

65. Nielsen NR, Truelsen T, Barefoot JC, Johnsen SP, Overvad K, Boysen G, et al. Is the Effect of Alcohol on Risk of Stroke Confined to Highly Stressed Persons? Neuroepidemiology. 2005;25(3):105-13.

66. Emberson JR, Shaper AG, Wannamethee SG, Morris RW, Whincup PH. Alcohol Intake in Middle Age and Risk of Cardiovascular Disease and Mortality: Accounting for Intake Variation Over Time. American Journal of Epidemiology. 2005;161(9):856-63.

67. Athyros VG, Liberopoulos EN, Mikhailidis DP, Papageorgiou AA, Ganotakis ES, Tziomalos K, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007;58(6):689-97.

68. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G. Metaanaylsis of Wine and Beer Consumption in Relation to Vascular Risk. Circulation 2002;105:2836-44.

69. Feigin VL, Rinkel GJE, Lawes CMM, Algra A, Bennet DA, van Gijn J, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 2005;36:2773-80.

70. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J; U.S. Preventive Services Task Force. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557-68.

71. Kaner EFS, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, et al. Efectividad de las intervenciones breves para controlar el consumo de alcohol en poblaciones que asisten a centros de atención primaria (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

72. Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. Reduction of alcohol consumption by brief intervention in primary care: systematic review and metaanalysis. Archives of Internal Medicine. 2005;165(9):986-95.

73. Ballesteros J, Duffy JC, Querejeta I, Arino J, Gonzales-Pinto A. Efficacy of brief interventions for hazardous drinkers in primary care: systematic review and metaanalysis. Alcoholism: Clinical and Experimental Research. 2004;28(4):608-18.

74. Scottish Intercollegiate Guidelines Network (SIGN). The management of harmful drinking and alcohol dependence in primary care. Edinburgh: SIGN; 2003 [Consultado el 19 de Marzo de 2008]. SIGN Publication No. 74. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/74/index.html Abre nueva ventana

75. Sociedad Española de Medicina de Familia y Comunitaria; Grupo de trabajo de alcohol de la semFYC. Recomendaciones semFYC: Alcohol. Barcelona (España); 2000.

76. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis. 2003;46(1):31-8.

77. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519-27.

78. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298(6676):789-94.

79. Wannamethee SG, Shaper AG, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet. 1998;351(9116): 1603-8.

80. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86-97.

81. World Health Organization. InternacionalAgency for research on Cancer (IARC). Involuntary smoking. IARC monographs, vol 83. Lyon (France): WHO; 2002.

82. Heidrich J, Wellmann J, Heuschmann PU, Kraywinkel K, Keil U. Mortality and morbidity from coronary heart disease attributable to passive smoking. Eur Heart J. 2007;28(20):2498-502.

83. Heuschmann PU, Heidrich J, Wellmann J, Kraywinkel K, Keil U. Stroke mortality and morbidity attributable to passive smoking in Germany. Eur J Cardiovasc Prev Rehabil. 2007;14(6):793-5.

84. López MJ, Pérez-Ríos M, Schiaffino A, Nebot M, Montes A, Ariza C, et al. Mortality attributable to passive smoking in Spain, 2002. Tob Control. 2007;16(6):373-7.

85. Stead LF, Lancaster T. Intervenciones para reducir los daños causados por el consumo continuo de tabaco (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

86. Lancaster T, Stead LF. Asesoramiento médico para el abandono del hábito de fumar (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

87. Silagy C, Lancaster T, Stead L, Mant D, Fowler G.Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD000146.

88. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031.

89. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006103.

90. Eisner MD, Smith AK, Blanc PD. Bartenders’ respiratory health after establishment of smoke-free bars and taverns. JAMA. 1998;280:1909-14.

91. Semple S, Miller BG, Hurley F, Petticrew M, Ayres JG. Respiratory Symptoms and Inflammation After a Smoking Ban. JAMA. 2007;297(4):359.

92. Allwright S, Paul G, Greiner B, Mullally BJ, Pursell L, Kelly A, et al. Legislation for smoke-free workplaces and health of bar workers in Ireland: before and after study. BMJ. 2005;331:1117-20.

93. Farrelly MC, Nonnemaker JM, Chou R, Hyland A, Peterson KK, Bauer UE. Changes in hospitality workers’ exposure to secondhand smoke following the implementation of New York’s smoke-free law. Tob Control. 2005;14:236-41.

94. Mulcahy M, Evans DS, Hammond SK, Repace JL, Byrne M. Secondhand smoke exposure and risk following the Irish smoking ban: an assessment of salivary cotinine concentrations in hotel workers and air nicotine levels in bars. Tob Control. 2005;14:384-8.

95. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban. BMJ. 2004;328:977-80.

96. Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPND). Observatorio Español sobre Drogas Informe nº 6. Madrid: DGPND. Ministerio del Interior; 2003 [consultado el 19 de Marzo de 2008]. Disponible en: http://www.mir.es/pnd/publica/pdf/oed-6.pdf Abre nueva ventana

97. Direcció General de Drogodependències i Sida. Atenció a les Drogodependències a Catalunya, 2001. Butlletí Epidemiològic de Catalunya 2003;23(4):49-52.

98. Díaz A, Pallarés J, Barruti M, Espluga J. Observatori de nous consums de drogues en l’àmbit juvenil: Informe 2003. Barcelona: Associació Institut GNEUS; 2004 [consultado el 19 de Marzo de 2008]. Disponible en: http://www.gencat.net/salut/ depsan/units/sanitat/pdf/obs2003.pdf Abre nueva ventana

99. Observatorio Español sobre Drogas. Encuesta sobre drogas a población escolar. 2002. Madrid DGPND Ministerio del Interior; 2003.

100. Petty GW, Brust JC, Tatemichi TK, Barr ML. Embolic stroke after smoking “crack” cocaine. Stroke. 1990;21(11):1632-5.

101. Sauer CM. Recurrent embolic stroke and cocaine-related cardiomyopathy. Stroke. 1991;22(9):1203-5.

102. Daras M, Tuchman AJ, Marks S. Central nervous system infarction related to cocaine abuse. Stroke. 1991;22(10):1320-5.

103. Sloan MA, Mattioni TA. Concurrent myocardial and cerebral infarctions after intranasal cocaine use. Stroke. 1992;23(3):427-30.

104. Sloan MA, Kittner SJ, Feeser BR, Gardner J, Epstein A, Wozniak MA, et al. Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study. Neurology. 1998;50:1688-93.

105. Martínez N, Díez-Tejedor E, Frank A. Vasospasm/thrombus in cerebral ischemia related to cocaine abuse. Stroke. 1996;27(1):147-8.

106. Levine SR, Washington JM, Jefferson MF, et al. “Crack” cocaine-associated stroke. Neurology. 1987;37(12):1849-53.

107. Golbe LI, Merkin MD. Cerebral infarction in a user of free-base cocaine (“crack”). Neurology. 1986;36(12):1602-4.

108. Khellaf M, Fenelon G. Intracranial hemorrhage associated with cocaine abuse. Neurology. 1998;50(5):1519-20.

109. Aggarwal SK, Williams V, Levine SR, Cassin BJ, Garcia JH. Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases. Neurology. 1996;46(6):1741-3.

110. Green RM, Kelly KM, Gabrielsen T, Levine SR, Vanderzant C. Multiple intracerebral hemorrhages after smoking “crack” cocaine. Stroke. 1990;21(6):957-62.

111. Wojak JC, Flamm ES. Intracranial hemorrhage and cocaine use. Stroke. 1987;18(4):712-5.

112. Moussotas M. Cannabis use and cerebrovascular disease. Neurologist. 2004; 10(1):47-53.

113. Mateo I, Pinedo A, Gómez-Beldarrain M, Basterretxea JM, García-Monco JC. Recurrent stroke associated with cannabis use. J Neurol Neurosurg Psychiatry. 2005;76(3):435-7.

114. Haubrich C, Diehl R, Donges M, Schiefer J, Loos M, Kosinski C. Recurrent transient ischemic attacks in a cannabis smoker. J Neurol. 2005;252(3):369-70.

115. Ohta K, Mori M, Yoritaka A, Okamoto K, Kishida S. Delayed ischemic stroke associated with methamphetamine use. J Emerg Med. 2005;28(2):165-7.

116. Hanyu S, Ikeguchi K, Imai H, Imai N, Yoshida M. Cerebral infarction associated with 3,4-methylenedioxymethamphetamine (‘Ecstasy’) abuse. Eur Neurol. 1995; 35(3):173.

117. Manchanda S, Connolly MJ. Cerebral infarction in association with Ecstasy abuse. Postgrad Med J. 1993;69(817):874-5.

118. Ho MP, Tsai JL, Wong YK. Subarachnoid hemorrhage and death following coingestion of MDMA with other drugs. J Chin Med Assoc. 2004;67(12):640-3.

119. Auer J, Berent R, Weber T, Lassnig E, Eber B. Subarachnoid haemorrhage with “Ecstasy” abuse in a young adult. Neurol Sci. 2002;23(4):199-201.

120. Buxton N, McConachie NS. Amphetamine abuse and intracranial haemorrhage. J R Soc Med. 2000;93(9):472-7.

121. Harries DP, De Silva R. ‘Ecstasy’ and intracerebral haemorrhage. Scott Med J. 1992;37(5):150-2.

122. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD. Marijuana use and mortality. Am J Public Health. 1997;87:85-90.

123. Petitti DB, Sidney S, Quesenberry C, Bernstein A. Stroke and cocaine or amphetamine use. Epidemiology. 1998;9:596-600.

124. Howington JU, Kutz SC, Wilding GE, Awasthi D. Cocaine use as a predictor of outcome in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(2):271-5.

125. Conway JE, Tamargo RJ. Cocaine use is an independent risk factor for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2001;32(10):2338-43.

126. Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med. 1990;113:821-7.

127. Sen S, Silliman SL, Braitman LE. Vascular risk factors in cocaine users with stroke. J Stroke Cerebrovasc Dis. 1999;8(4):254-8.

128. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation. 2001;103(4):502-6.

129. Kaufman MJ, Levin JM, Ross MH, Lange N, Rose SL, KukesTJ, et al. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA. 1998;279:376-80.

130. Siegel AJ, Sholar MB, Mendelson JH, Lukas SE, Kaufman MJ, Renshaw PF, et al. Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood dping and prothrombotic effects. Arch Intern Med. 1999;159:1925-9.

131. Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol. 2000;7:595-606.

132. Practice Guideline for the Treatment of Patients With Substance Use Disorders (Second Edition). Arlington, VA (EEUU): American Psychiatric Association (APA); 2006 Agosto. 263 p.

133. Leon AS, Sanchez OA. Response of blood lipids to exercice training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001;33(6Suppl):S502-15.

134. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercice on blood pressue: a meta-analysis of randomized controlled trials. Ann Intern Med. 2002;136:493-503.

135. Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, et al. Physical activity and stroke. A meta-analysis of observational data. Int J Epidemiol 2004;33(4):787-98.

136. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003;34(10):2475-81.

137. OgumaY, Shinoda-Tagawa T. Physical activity decreases cardiovascular disease risk in women: review and meta-analysis. Am J Prev Med. 2004;26(5):407-18.

138. Hamer M, Chida Y. Active commuting and cardiovascular risk: A meta-analytic review. Prev Med. 2008;46(1):9-13.

139. Serra L, Helsing E (Editors). Changing patterns of fat intake in Mediaterranean countries. Eur J Clin Nutr. 1993, 47 (supp 1):S1-S100.

140. Eyre H, Kahn R, Roberson RM, Clark NG, Doyle C, Hong Y, et al. Preventing Cancer, Cardiovascular Disease and Diabetes. A common Agenda for the American Diabetes Association, and the American Heart Association. Circulation. 2004;109:3244-55.

141. Pla de salut de Catalunya 2002-2005. Hàbits alimentaris. Barcelona: Direcció General de Salut Pública. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya. Ediciones Doyma. Barcelona 2003:143-156.

142. Serra L, Ribas L. Avaluació de l’estat nutricional de la població catalana 2002-2003. Direcció General de Salut Pública. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya.

143. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database of Systematic Reviews. 2000, Issue 2. Art. No.:CD002137.

144. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):655-66.

145. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD003177.

146. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, Goldbourt U, Greenland P. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke. 2004;35(7):1538-42.

147. Feng FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke. Lancet. 2006;367:320-6.

148. Dauchet L, Amouyel P, Dallongeville J. Fruit and vegetable consumption and risk of stroke: A meta-analysis of cohort studies. Neurology. 2005;65:1193-97.

149. Burton GW, Joyce A, Ingold KU. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membrane? Arch Biochem Biophys. 1983;221:281-90.

150. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004;164(14):1552-6.

151. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-9.

152. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-5.

153. Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women. Results From the Women’s Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167:1610-18.

154. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007176.

155. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a metaanalysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16(11):761-70.

156. Hooper L, Bartlett C, Davey SG, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 2002;325:628.

157. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, et al. como Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación Española de la Guía Europea de Prevención Cardiovascular. Rev Esp Salud Pública. 2004;78:435-8.

158. Organización Mundial de la Salud. Obesidad y sobrepeso [página web en Internet]. Ginebra (Suiza): Organización Mundial de la Salud. Nota descriptiva 311 [actualizado Septiembre de 2006; consultado el 19 Marzo de 2008]. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/index.html Abre nueva ventana

159. WHO. Diet, nutrition and the prevention of chronic diseases. Report of a Joint FAO/WHO Expert consultation. WHO Technical report series 916. WHO: Geneva (Switzerland); 2003.

160. Lindström M, Isacsson SO, Merlo J. Increasing prevalence of overweight, obesity and physical inactivity: two population-based studies 1986 and 1994. Eur J Public Health. 2003;13(4):306-12.

161. Gutiérrez-Fisac JL, Regidor E, Banegas JR, Rodríguez Artalejo F. Prevalence of obesity in the Spanish adult population: 14 years of continuous increase. Med Clin (Barc). 2005;124(5):196-7.

162. Felgal KM, Caroll MD, Odgen L, Johnson L. Prevalence and trends in obesity among US adults 1999-2000. JAMA. 2002;288:1723-7.

163. Odgen L, Felgal KM, Caroll MD. Prevalence and trends in overweight among US children and adolescents 1999-2000. JAMA. 2002;288:1728-32.

164. Serra L, Ribas L, Aranceta J, Pérez-Rodrigo C, Saavedra P. Epidemiología de la obesidad infantil y juvenil en España. Resultados del estudio enKid (1998-2000). Vol 2. Barcelona:Masson; 2002. p: 81-108.

165. Aranceta Bartrina J, Serra Majem L, Ribas Barba L, Pérez Rodrigo C. Factores determinantes de la obesidad de la población infantil y juvenil española. En: Serra Majem L, Aranceta Bartrina J, editores. Obesidad en la población infantil y juvenil española. Estudio enKid (1998-2000). Barcelona:Masson; 2001. p: 109-28.

166. Obesity: preventing and managing the global epidemic. Report of aWHO consultation. World Health Organ Tech Rep Ser. 2000;160:894:i-xii:1-253.

167. McGee DL, Diverse Populations Collaboration. Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol. 2005;15(2):87-97.

168. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867-72.

169. Hu G, Tuomilehto J, Silventoinen K, Barengo N, Jousilahti P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. Eur Heart J. 2004;25(24):2212-9.

170. Ajani UA, Lotufo PA, Gaziano JM, Lee IM, Spelsberg A, Buring JE, et al. Body mass index and mortality among US male physicians. Ann Epidemiol. 2004; 14(10):731-9.

171. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases-report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci. 2002;15(3):245-52.

172. Calle EE, Rodríguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.

173. Baik I, Ascherio A, Rimm EB, Giovannucci E, Spiegelman D, Stampfer MJ, et al. Adiposity and mortality in men. Am J Epidemiol. 2000;152(3):264-71.

174. Baker JL, Olsen LW, Sørensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007;357(23):2329-37.

175. Abbott RD, Behrens GR, Sharp DS, Rodríguez BL, Burchfield CM, Ross GW, et al. Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart Program. Stroke. 1994;25(12):2370-6.

176. Jood K, Jern C, Wilhelmsen L, Rosengren A. Body mass index in mid-life is associated with a first stroke in men: a prospective population study over 28 years. Stroke. 2004;35:2764-9.

177. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, et al. Body mass index and the risk of stroke in men. Arch Intern Med. 2002;162:2557-62.

178. Milionis HJ, Goudevenos J, Seferiadis K, Elisaf MS. Associations between body mass index and risks in elderly patients with a first-ever acute ischemic stroke [letter]. Arch Intern Med. 2003;163:980.

179. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men. Stroke. 2004;35:831-6.

180. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich- Edwards JW, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277:1539-45.

181. Folsom AR, Prineas RJ, Kaye SA, Munger RG. Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke. 1990;21:701-6.

182. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ. 1984;289:1257-61.

183. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13- years follow-up of participants in the study of men born in 1913. BMJ. 1984;288:1401-4.

184. Lindenstrom E, Boysen G, Nyboe J. Lifestyle factors and the risk of cerebrovascular disease in women: the Copenhagen City Stroke Study. Stroke. 1993;24:1468-72.

185. Njølstad I, Arnesen E, Lund-Larsen PG. Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women: a 14-year follow-up of the Finmark Study. Circulation. 1996;94:2877-82.

186. Stokes J III, Kannel WB, Wolf PA, Cupples LA, D’Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation. 1987;75 Suppl V: V65-V73.

187. Dey DK, Rothenberg E, Sundh V, Bosaeus I, Steen B. Waist circumference, body mass index, and risk for stroke in older people: a 15 year longitudinal population study of 70 year-olds. J Am Geriatr Soc. 2002;50:1510-8.

188. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, ElkindMS, et al. For the Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34:1586-92.

189. Curioni C, André C, Veras R. Reducción de peso para la prevención primaria del accidente cerebrovascular en adultos con sobrepeso u obesidad (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

190. Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, Anagnostelis B. Dieting to reduce body weight for controlling hypertension in adults. Cochrane Database of Systematic Reviews 1998, Issue 4. Art. No.: CD000484.

191. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17(4):317-35(a).

192. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17(4):293-316(b).

193. Neter JE, Stam BE, Kok FJ, Grobbee DE, Gelejinse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-884.

194. Shaw K, Gennat H, O’Rourke P, Del Mar C. Ejercicio para el sobrepeso o la obesidad (Revisión Cochrane traducida). En:La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

195. McTigue, Harris R, Hemphill B, Lux L, Sutton S, Bunton A, et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. preventive task force. Ann Intern Med. 2003;139:933-49.

196. Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO). En: Clinical Trials.gov website. [consultado el 19 de Marzo de 2008]. Accesible en: http://www.clinicaltrials.gov Abre nueva ventana

197. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007;28:2915-23.

198. Maggard MA, Shugarman LR, Suttorop M, Maglione M, Sugerman HJ, Livingstone EH, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547-59.

199. Buchwald H, Avidor Y, Braunwald E, jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292(14):1724-37.

200. Gorelick PB. Stroke prevention: windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal. Neuroepidemiology. 1997;16:163-73.

201. Maiques Galán A, Villar Álvarez F, Brotons Cuixart C, Torcal Laguna J, Orozco- Beltrán D, Navarro Pérez J, et al. Recomendaciones preventivas cardiovasculares. Aten Primaria. 2007;39(Supl 3):15-26.

202. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-71.

203. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-7.

204. Rywik SL, Davis CE, Pajak A, Broda G, Folsom AR, Kawalec E, et al. Poland and US Collaborative Study on Cardiovascular Epidemiology: hypertension in the community: prevalence, awareness, treatment, and control of hypertension in the Pol- MONICA Project and the US Atherosclerosis Risk in Communities study. Ann Epidemiol. 1998;8:3-13.

205. Banegas J. Epidemiología de la hipertensión arterial en España. Situación actual y perspectivas. Hipertensión. 2005;22:253-362.

206. Gil-Núñez AC, Vivancos-Mora J, Gabriel R, Nombela-Merchán, for the Cerebrovascular Diseases Study Group for the Spanish Society of Neurology: Assessment of ischemic stroke diagnostic and secondary prevention practices, in Spain. The DIAPRESIC Study. Cerebrovasc Dis. 2004;17(suppl 5):52-53.

207. Redón J, Cea-Calvo L, Lozano J, Martí-Canales JC, Llisterri JL, Aznar J, et al. Blood pressure and estimate risk of stroke in the elderly population of Spain. The PREV-ICTUS Study. Stroke. 2007;38:1167-1173.

208. Redón J, Cea-Calvo L, Lozano JV, Martí-Canales JC, Llisterri JL, Aznar J, et al. Differences in blood pressure control and stroke mortality across Spain: the Prevención de Riesgo de Ictus (PREV-ICTUS) study. Hypertension. 2007;49(4):799-805.

209. Dickinson HO, Manson JM, Nicolson DJ, Campbell F, Beyer FR, Cook SW, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomised controlled trials. J Hypertens. 2006;24:215-33.

210. Ebrahim S, Beswick A, Burke M, Davey Smith G. Intervenciones sobre múltiples factores de riesgo para la prevención primaria de la cardiopatía coronaria (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

211. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as firstline agents: a network meta-analysis. JAMA. 2003;289(19):2534-44.

212. Trumbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-35.

213. Mulrow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000028.

214. Quan A, Kerlikowske K, Gueyffier F, Boissel JP, for the INDANA Investigators. Pharmacotherapy for hypertension in women of different races. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD002146.

215. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A metaanalysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997;126:761-7.

216. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly:meta-analysis of outcome trials. Lancet. 2000;355:865-72.

217. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28(5):385-407.

218. Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and young adults: a meta-analysis of randomised trials. BMJ. 2008;336 (7653):1121-23.

219. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Betablockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002003.

220. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-42.

221. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31.

222. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure LoweringArm (ASCOT-BPLA): a multicentre randomised controlled trial.Lancet. 2005;366(9489):895-906.

223. Rotaeche del Campo R, Aguirrezabala Jaca J, Balagué Cea L, Gorroñogoitia Iturbe A, Idarreta Mendiola I, Mariñelarena Mañeru E, Mozo Avellaned C, Ruiz de Velasco Artaza E, Torcal Laguna J. Guía de Práctica Clínica sobre Hipertensión Arterial (actualización 2007). Osakidetza. GPC. Vitoria-Gasteiz; 2008.

224. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J. 2007; 28(12):1462-536.

225. Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy. 2001;21(8):940-53.

226. Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-9.

227. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29-35.

228. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62.

229. Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:776-785.

230. National Institute for Clinical Excellence. Clinical Guideline F. Management of type 2 diabetes. Renal disease-prevention and early management. London: National Institute for Clinical Excellence; 2002.

231. Grupo de Trabajo de la Guía de Práctica Clínica sobre Diabetes tipo 2. Guía de Práctica Clínica sobre Diabetes tipo 2. Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluación de Tecnologías Sanitarias del País Vasco; 2008. Guías de Práctica Clínica en el SNS: OSTEBA Nº 2006/09.

232. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345(12):861-9.

233. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-8.

234. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.

235. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20(11):2099-110.

236. Giroud M, Gras P, Chadan N, Beuriat P, Milan C, Arveux P, et al. Cerebral haemorrhage in a French prospective population study. J Neurol Neurosurg Psychiatry. 1991;54(7):595-8.

237. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38(6):2001-23.

238. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and casefatality in the late 20th century. Lancet Neurol. 2003;2:43-53.

239. Perry HM Jr, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465-71.

240. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke. 2004;35:116-21.

241. King H, Rewers M. Global estimates for prevalence for diabetes mellitus and impaired glucose tolerance in adults. WHO ad hoc Diabetes Reporting Group. Diabetes Care. 1993;16:157-77.

242. Castell C, Treserras R, Serra J, Goday A, Lloveras G, Salleras Ll. Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin. 1999;43:33-40.

243. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care. 1997;20:127-8.

244. Folsom AR, Rasmussen ML, Chambless ME, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care. 1999;22:1077-83.

245. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol. 1988;128:116-123.

246. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Evidence Report/Technology Assessment No. 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02- 0020). AHRQ Pub.No 05-E026-2. Rockville, MD: Agency for Healthcare Research and Quality. September 2005.

247. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(7588):299.

248. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De GrauwWJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005061.

249. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005270.

250. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005;28(11):2780-6.

251. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-94.

252. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541):1096-105.

253. Singh S, Loke YK, Furberg CD. Thiazolidinediones and Heart Failure: A teleoanalysis. Diabetes Care. 2007;30(8):2148-53.

254. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-8.

255. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.

256. Singh S, Loke YK, Furberg CD. Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis. JAMA. 2007;298(10):1189-95.

257. Riesgo cardiaco asociado a rosiglitazona. Comunicación de la AEMPS sobre datos recientemente publicados. Nota informativa 2007/08 de la AEMPS Agencia Española de Medicamentos y Productos Sanitarios. 2007 [Acceso Septiembre 2007]. Disponible en http://www.agemed.es/actividad/alertas/usoHumano/seguridad/rosiglitazona-mayo07.htm Abre nueva ventana

258. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 2005;48:1726-35.

259. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(17):1-144.

260. US Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med. 2003;138(3):212-4.

261. Grupo de estudio para la diabetes en atención primaria de salud (GEDAPS). Guía para el tratamiento de la diabetes tipo 2 en la atención primaria. 4ª ed; 2004.

262. Estrategia en diabetes del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo. Centro de publicaciones; 2007.

263. Departament de Sanitat i Seguretat Social. Examen de salut a la població de Catalunya de 18 a 74 anys. [consultado el 20 de Marzo de 2008]. Disponible en: http://www.gencat.net/salut/depsan/units/sanitat/pdf/ Abre nueva ventana

264. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274(2):131-6.

265. Hachinski V, Graffagnio C, Beaudry M, Bernier G, Buck C, Donner A, et al. Lipids and stroke: a paradox resolved. Arch Neurol 1996;53(4):303-8.

266. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39.

267. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46(10):1855-62.

268. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1993;119(2):136-45.

269. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMGCoA reductase inhibitors. Stroke. 1997;28(5):946-50.

270. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128(2):89-95.

271. Ross SD, Allen IE, Connelly JE et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159(15):1793-802.

272. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther. 2003;41(12):567-77.

273. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57:640-51.

274. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.

275. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008;121(1):24-33.

276. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(21):2307-13.

277. Nakamura H, Arakawa K, Itakura H, Kitabatake A, GotoY, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial, Lancet. 2006; 368(9542):1155-1163.

278. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004;117(8):596-606.

279. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004 Dec;35(12):2902-9.

280. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention. A meta-analysis of randomized trials. Arch Intrern Med. 2003;163:669-676.

281. Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM. Impact of gender on statin efficacy. Curr Med Res Opin. 2007;23(3):565-74.

282. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25.

283. Vijan S, Hayward RA; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140(8):650-8.

284. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332(7550):1115-24.

285. [BlueCross Report] Special Report: The Efficacy and Safety of Statins in the Elderly. BlueCross BlueChield Association. Assessment Program Volume 21, No. 12. February 2007. [consultado el 20 de Marzo de 2008]. Disponible en: http://www.bcbs.com/betterknowledge/tec/vols/21/21_12.pdf Abre nueva ventana

286. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C-94C.

287. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74-80.

288. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events fromHMGCo Areductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf. 2007;16:132-43.

289. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006; 97(8A):52C-60C.

290. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co A) reductase inhibitors: drugdrug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71-105.

291. Cooper A, Nherera L, Robson J, O’Flynn N , Turnbull N, Camosso-Stefinovic J, et al. (2007). Clinical guidelines and evidence review for cardiovascular risk assessment: the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2007.

292. Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, et al. Statin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-43.

293. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabet Metab. 2002;28:364-376.

294. GilA. The metabolic syndrome and cerebrovascular disease: suspicion and evidence. Cerebrovascular Dis. 2007;24(suppl 1):64-75.

295. Arenillas JF, Moro MA, Davalos A. The metabolic syndrome and stroke: potential treatment approaches. Stroke. 2007;38(7):2196-203.

296. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol. 2007;49:403-14. 297. Galassi A, Reynolds K, He J. Metabolic Syndrome and Risk of Cardiovascular Disease: A Meta-Analysis. Am J Med.2006;119(10):812-9.

298. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke. 2006;37(4):1060-4.

299. Wiberg B, Sundstrom J, Arnlöv J, Terént A, Vessby B, Zethelius B, et al. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: A community- based study with long-term follow-up. Stroke. 2006;37(12):2898-903.

300. Gillum LA, Johnston SC. Oral Contraceptives and Stroke Risk: the Debate Continues. Lancet Neurology. 2004;3(8):453-4.

301. Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med. 2004;164(7):741-7.

302. Baillargeon JP, Mcclish DK, Essah PA, Nestler JE. Association Between the Current Use of Low-Dose Oral Contraceptives and Cardiovascular Arterial Disease: a Meta-Analysis. J Clin Endocrinol Metab. 2005;90(7):3863-70.

303. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives. A meta-analysis. JAMA. 2000;284:72-8.

304. Johnston SC, Colford JM, Gress DR. Oral contraceptives and the risk of subarachnoid hemorrhage. A meta-analysis. Neurology. 1998;51:411-8.

305. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006;107(7):2766-73.

306. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral Contraceptive Use, Thrombophilia and Their Interaction in Young Women With Ischemic Stroke. Haematologica. 2006;91(6):844-7.

307. Siritho S, Thrift AG, Mcneil JJ, You RX, Davis SM, Donnan GA. Risk of Ischemic Stroke Among Users of the Oral Contraceptive Pill - The Melbourne Risk Factor Study (Merfs) Group. Stroke. 2003;34(7):1575-80.

308. Li Y, Zhou L, Coulter D, Gao E, Sun Z, Lu Y, et al. Prospective cohort study of the association between use of low-dose oral contraceptives and stroke in Chinese women. Pharmacoepidemiol Drug Saf. 2006;15(10):726-34.

309. Jick SS, Jick H. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy. 2007;27(2):218-20.

310. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47-63.

311. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.

312. Gabriel SR, Carmona L, Roque M, Sánchez GL, Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD002229.

313. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77.

314. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239.

315. Orúe MT. Trombofilia e ictus. ANALES Sis San Navarra. 2000;23(Supl.3):39-45.

316. Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch Dis Child. 2005;90(4):402-5.

317. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J. 2003;146:948- 57.

318. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.N Engl JMed. 1995;332:912-7.

319. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost. 1998;79:912-5.

320. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547-53.

321. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100(1):3-10.

322. Rahemtullah A, Van Cott EM. Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med. 2007;131:890-901.

323. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in large cohort of US men. Circulation. 1999;99:999-1004.

324. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-6.

325. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CKL, et al. beta(2)- Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32:1701-6.

326. Janardhan V, Wolf PA, Kase CS, Massaro JM, D’Agotino RB, Franzblau C, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004;35:736-41.

327. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295(9):1050-7.

328. Brey RL. Management of the neurological manifestations of APS-what do the trials tell us? Thromb Res. 2004;114(5-6):489-99.

329. Gatenby PA. Controversies in the antiphospholipid syndrome and stroke. Thromb Res. 2004;114(5-6):483-8.

330. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-22.

331. Hackman DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290(7):932-40.

332. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202.

333. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ. 2006; 333(7578):1114-7.

334. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224-32.

335. Nygård O, Nordehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-36.

336. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296:2720-6.

337. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876-82.

338. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Metaanalysis of prospective studies. Circulation. 2000;102:1082-5.

339. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007;38:1959-66.

340. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O’Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737-43.

341. Gil-Núñez AC, Vivancos-Mora J. Women and strokes: specific therapy for female patients. Rev Neurol. 2003;37(9):845-859.

342. Bousser MG, Welch KMA. Relation Between Migraine and Stroke. Lancet Neurology. 2005;4(9):533-42.

343. Weinberger J. Stroke and migraine. Current Cardiology Reports. 2007;9(1):13-9.

344. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330(7482):63.

345. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology. 2005;64(6):1020-6.

346. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296(3):283-91.

347. Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med. 2007;167(8):795-801.

348. Stang PE, Carson AP, Rose KM et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 2005;64(9):1573-7.

349. Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol. 2007;101(1):3-14.

350. Mehta SH, Adams RJ. Treatment and prevention of stroke in children with sickle cell disease. Curr Treat Options Neurol. 2006;8(6):503-12. 351. Abboud MR, Atweh GF. Prevention and management of strokes in patients with sickle cell disease. Curr Hematol Rep. 2006;5(1):15-22.

351. Abboud MR, Atweh GF. Prevention and management of strokes in patients with sickle cell disease. Curr Hematol Rep.2006;5(1):15-22

352. Howard J, Davies SC. Sickle cell disease in North Europe. Scand J Clin Lab Invest. 2007;67(1):27-38.

353. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-94.

354. Hulbert ML, Scothorn DJ, Panepinto JA, Scott JP, Buchanan GR, Sarnaik S, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr. 2006;149:710-712.

355. Hirst C, Wang WC. Blood transfusion for preventing stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003146.

356. [NICE-AF] National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians; 2006.

357. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace. 2006;8(9):651-745.

358. Singer DE, AlbersGW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the SeventhACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;26(3 Suppl):429S-456S.

359. Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. Edinburgh: SIGN; 2007 [consultado el 19 de Marzo de 2008]. SIGN Publication No. 93. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/93/index.html Abre nueva ventana

360. Cooper A, Skinner J, Nherera L, Feder G, Ritchie G, Kathoria M, et al. Clinical Guidelines and Evidence Review for Post Myocardial Infarction: Secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2007.

361. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. ESC Committee for Practice guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230-68.

362. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke:The Framingham Study. Stroke. 1991;22:983-8.

363. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study. JAMA. 2003;290:1049-56.

364. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.

365. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 1999;131:492-501.

366. Levy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns H, et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace. 2003;5(2):119-122.

367. Lip GY, Boos C. Antithrombotic therapy for atrial fibrillation. Heart. 2006;92:155-61. 368. Kalra L, LipGY. Antithrombotic treatment for atrial fibrillation. Heart. 2007;93:39-44.

368. Kalra L, Lip GY. Antithrombotic treatment for atrial fibrillation. Heart. 2007;93:39-44

369. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-96.

370. Kakar P, Lane D, Lip GYH. Bleeding risk strati. cation models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest. 2006;130:1296-99.

371. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.

372. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-60.

373. Shireman T, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfari recipients. Chest. 2006;130:1390-6.

374. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation. Changing physician-related factors. Stroke. 2008;39:7-9.

375. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD001925.pub2.

376. Aguilar M, Hart R. Oral anticoagulants for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001927.pub2.

377. Aguilar M, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006186.

378. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.

379. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118(3):321-33.(b)

380. Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose. A meta-analysis. Thromb Haemost. 2004;91(2):394-402.

381. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Pertersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441-2448.

382. Healey JS, Hart RG, Pouge J, Pfeffer MA, Hohnloser SH, De Caterina R, et al. Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke. 2008;39(5)1482-6. [Epub ahead of print].

383. Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atriall fibrillation. J Am Coll Cardiol. 2004; 44(8):1557-66.

384. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.

385. The AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with arterial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371:315-21.

386. Lip GYH, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ. Oral anticoagulation in atrial fibrillation: A pan-European patient survey. Eur J Intern Med. 2007;18(3):202-8.

387. Man-Son-Hing M, Gage BF, Montgomery AA, Howitt A, Thomson R, Devereaux PJ, Protheroe J, Fahey T, Armstrong D, Laupacis A. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making. 2005;25(5):548-59.

388. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323(7323):1218-1222.

389. Odegaard KJ. [Self-management in anticoagulationa – a meta-analysis]. Tidsskr Nor Laegeforen. 2004;124:2900-03.

390. Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost. 2004;91:225-32.

391. Heneghan C, Alonso-Coello P, García-Alamino J, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367:404-11.

392. Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007;118(1):54-61.

393. Brown A, Wells P, Jaffey J, McGahan L, Poon M-C, Cimon K, Campbell K. Point-ofcare monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness [Technology report no 72]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.

394. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing longterm oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11(38):iii-iv, ix-66.

395. Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of selfmanaged versus physician-managed oral anticoagulation therapy. CMAJ. 2006 Jun 20;174(13):1847-52.

396. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the rosk of 6-months postdischarge death in an international registry. JAMA. 2004;291(22):2727-33.

397. Wienbergen H, Schiele R, Gitt AK, Schneider S, Heer T, Gottwik M, et al. for the Myocardial Infarction Registry (MIR) and Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Groups. Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice. Am J Cardiol. 2001;87:782-5.

398. Tanne D, Gottlieb S, Hod H, Reicher-Reiss H, Boyko V, Behar S, for the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) and Israeli Thrombolytic Survey Groups. Incidence and mortality from early stroke associated with acute myocardial infarction in the prethrombolytic and thrombolytic eras. J Am Coll Cardiol. 1997;30:1484-90.

399. Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction: a population-based study. Stroke. 1997;28:762-7.

400. Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, et al. Risk factors for inhospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTOI. Circulation. 1998;97:757-64.

401. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-7.

402. Spirito P, Bellotti P, Chiarella F, Domenicucci S, Sementa A, Vecchio C. Prognostic significance and natural history of left ventricular thrombi in patients with acute anterior myocardial infarction: a two-dimensional echocardiographic study. Circulation. 1985;72:774-80.

403. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.

404. Gent M. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-39.

405. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966-72.

406. Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. Edinburgh: SIGN; 2007 [Consultado el 19 de Marzo de 2008]. SIGN Publication No. 93. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/93/index.html Abre nueva ventana

407. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet. 2005;366:1607-21.

408. Sabatine MS, Cannon CP, Gibson BJ, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Eng J Med. 2005;352:1179-89.

409. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282(21):2058-67.

410. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347(13):969-974.

411. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE, Antithrombotics. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-113.

412. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk benefit. Ann Intern Med. 2005;143:241-50.

413. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39.

414. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993;87: VI94-101.

415. Lip GYH. Intracardiac thrombus formation in cardiac impairment: Investigation and the Role of Anticoagulant Therapy. Postgrad Med J. 1996;72:731-38.

416. Lip GYH, Chung I. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database of Systematic Reviews. 2000, Issue 2. Art. No.: CD003333.

417. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157-64.

418. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79:909-13.

419. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10(2):101-12.

420. Laplace G, Lafitte S, Labeque JN, Perron JM, Baudet E, Deville C, et al. Clinical significance of early thrombosis after posthetic mitral alave replacement: a prospective monocentric study of 680 pacients. J Am Coll Cardiol. 2004;43:1283-90.

421. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111-9.

422. Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G, et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998;98:II95-98.

423. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110:496-500.

424. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg. 2005;129:1024-31.

425. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: Original report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36:1152-8.

426. Little SH, Massel DR. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD003464.

427. Aramendi JI, Mestres CA, Martínez-León J, Campos V, Muñoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg. 2005;27(5):854-60.

428. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31:749-53.

429. Brueck M, Kramer W, Vogt P, Steinert N, Roth P;Görlach G, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg. 2007;32(1):108-12.

430. Wood P. An appreciation of mitral stenosis, I: clinical features. Br Med J. 1954;4870:1051-63. 431. Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J. 1970;32: 26-34.

431. Coulshed N, Epstein EJ, McKendrick CS, Gallovay RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J. 1970;32:26-34.

432. Adams GF, Merrett JD, Hutchinson WM, Pollock AM. Cerebral embolism and mitral stenosis: survival with and without anticoagulants. J Neurol Neurosurg Psych. 1974;37:378-83.

433. Abernathy WS, Willis PW 3rd. Thromboembolic complications of rheumatic heart disease. Cardiovasc Clin. 1973;5(2):131-75.

434. Caplan LR, D’Cruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation, and stroke. Ann Neurol. 1986;19:158-61.

435. Cassella K, Abelmann WH, Ellis LB. Patients with mitral stenosis and systemic emboli. Arch Intern Med. 1964;114:773

436. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med. 1992;116(1):6-12.

437. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31(7):1622-6.

438. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998;128(8):639-47.

439. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279:1273-7.

440. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999;341:1-7.

441. Rosenberg CA, Derman GH, Grabb WC, Buda AJ. Hypomastia and mitral-valve prolapse: evidence of a linked embryologic and mesenchymal dysplasia. N Engl J Med. 1983;309:1230-2.

442. Zuppiroli A, Rinaldi M, Kramer-Fox R, Favilli S, Roman MJ, Devereux RB.Natural history of mitral valve prolapse. Am J Cardiol. 1995;75:1028-32.

443. Nishimura RA, McGoon MD, Shub C, Miller FA Jr., Ilstrup DM, Tajik AJ. Echocardiographically documented mitral-valve prolapse: long-term follow-up of 237 patients. N Engl J Med. 1985;313:1305-9.

444. Avierinos JF, Gersh BJ, Melton LJ III, Bailey KR, Shub C, Nishimura RA , et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation. 2002;106:1355-61.

445. Marks AR, Choong CY, San.lippo AJ, Ferre M, Weyman AE. Identification of highrisk and low-risk subgroups of patients with mitral-valve prolapse. N Engl J Med. 1989;320:1031-6.

446. Bonow RO, Carabello BA, Kanu C, de Leon Ac, Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006;114(5):e84-231.

447. Nadareishvili ZG, Rothwell PM, BeletskyV, Pagniello A, Norris JW. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol. 2002;59:1162-6.

448. Álvarez García B, Escribano Ferrer JM, Matas Docampo M. Isquemia Cerebrovascular Extracraneal, Bases generales y Diagnóstico en: Tratado de las Enfermedades Vasculares, Vol II. Barcelona: Viguera; 2006. p. 711-728.

449. O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK Jr, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke. 1992;23(12):1752-60.

450. Abbott AL, Chambers BR, Stork JL, Levi CR, Bladin CF, Donnan GA. Embolic signals and prediction of ipsilateral stroke or transient ischemic attack in asymptomatic carotid stenosis: a multicenter prospective cohort study. Stroke. 2005;36(6):1128-33.

451. Fairhead JF, Rothwell PM, Pete PM. Underinvestigation and undertreatment of carotid disease in elderly patients with transient ischaemic attack and stroke: comparative population based study. BMJ. 2006;333:525-7.

452. Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews. 2005, Issue 4. Art. No.: CD001923.

453. Connors JJ, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, et al. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Neurology. 2005;64(2):190-8.

454. Bond R, Rerkasem K, Cuffe R, Rothwell PM. A Systematic Review of the Associations between Age and Sex and the Operative Risks of Carotid Endarterectomy. Cerebrovasc Dis. 2005;20:69-77.

455. Bond R, Rerkasem K, Rothwell PM. Systematic Review of the Risks of Carotid Endarterectomy in Relation to the Clinical Indication for and Timing of Surgery. Stroke. 2003;34;2290-1.

456. Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD001458. DOI:10.1002/14651858. CD001458.

457. Kilaru S, Korn P, Kasirajan K, Lee TY, Beavers FP, Lyon RT, et al. Is carotid angioplasty and stenting more cost effective than carotid endarterectomy? J Vasc Surg. 2003;37(2):331-9.

458. Park B, Mavanur A, Dahn M, Menzoian J. Clinical outcomes and cost comparison of carotid artery angioplasty with stenting versus carotid endarterectomy. J Vasc Surg. 2006;44(2):270-6.

459. Luebke T, Aleksic M, Brunkwall J. Meta-analysis of Randomized Trials Comparing Carotid Endarterectomy and Endovascular Treatment. Eur J Vasc Endovasc Surg 2007;34:470-9.

460. Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660-71.

461. Gurm HS, Yadav JS, Fayad P, Katzen BT Mishkel GJ, Bajwa TK, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008;358:1572-9.

462. Wolff T, Guirguis-Blake J, Miller T, Gillespie M, Harris R. Screening for Asymptomatic Carotid Artery Stenosis. Evidence Synthesis no. 50. AHRQ publication no. 08-05102-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; December 2007 [consultado el 20 de Marzo de 2008]. Disponible en: www.preventiveservices.ahrq.gov Abre nueva ventana

463. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98(6):746-50.

464. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163(17):2006-10.

465. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136(2):161-72.

466. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other Major vascular events: meta-analysis and hypotheses. Arch Neurol. 2000;57:326-32.

467. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85(3):265-71.

468. Ibáñez L, Vidal X, Vendrell L, Moretti U, Laporte JR, Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006; 23(2):235-42.

469. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. JAMA. 2007;297(18):2018-24.

470. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin- associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348(9039):1413-6.

471. Derry, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183-7.

472. García-Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiological studies. Br J Clin Pharmacol. 2001;52(5):563-71.

473. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306-13.

474. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26:3264-72.

475. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992 Sep 9;268(10):1292-300.

476. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):627S-644S.

477. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.

478. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-9.

479. Aspinall SL, DeSanzo BE, Trilli LE, Good CB. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med. 2005;20:1008-13.

480. Viennet D, Cannamela A, Gonthier R. Oral anticoagulant-related hemorrhagic complications in emergency ward patients aged 75 and over: Contribution of a predictive bleeding index. Jeur. 2004;17:15-20.

481. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med. 2003;163:917-20.

482. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-60.

483. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390-6.

484. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-719.

485. Sarti C, Tuomilehto J, Salomaa V, Sivenius J, Kaarsalo E, Harva EV, et al. Epidemiology of subarachnoid hemorrhage in Finland from 1983 to 1985. Stroke. 1991;22:848-53.

486. KiyoharaY,Ueda K, HasuoY, Wada J, Kawano H, Kato I, et al. Incidence and prognosis of subarchnoid in Japanese rural community. Stroke. 1989;20:1150-5.

487. Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of Subarachnoid and intracerebral hemorrhages in blacks as compared with withes. N Engl J Med. 1992;326:733-6.

488. Inagawa T, TokudaY, Ohbayashi N, Takayama M, Moritake K. Study of aneurysmal subarachnoid hemorrhage in Izumo City, Japan. Stroke. 1995;26:761-6.

489. Kopitnik TA, Samson DS. Management of subarachnoid hemorrhage. L Neurol Neurosurg Psychiatry. 1993;56:947-59.

490. Van Crevel H, Habbema JD, Braakman R. Decision analysis of the management of incidental intracraneal saccular aneurysms. Neurology. 1986;36:1335-9.

491. Ferguson GG. Physical factors in the initiation, growth, and rupture of human intracranial saccular aneurysms. J Neurosurg. 1972;37:666-77.

492. Sekhar LN, Heros RC. Origin, growth, and rupture of saccular aneurysms: a review. Neurosurgery. 1981;8:248-60.

493. Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. Stroke. 2007;38(4):1404-10.

494. Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362:103-10.

495. Higashida RT, Lahue BJ, Torbey MT, Hopkins LN, Leip E, Hanley DF. Treatment of unruptured intracranial aneurysms: a nationwide assessment of effectiveness. AJNR Am J Neuroradiol. 2007;28(1):146-51.

496. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA. Early Risk of Stroke After Transient Ischemic Attack: A Systematic Review and Meta-analysis. Arch Intern Med. 2007;167:2417-22.

497. Kaplan RC, Tirschwell DL, Longstreth WT, Manolio TA, Heckbert SR, Lefkowitz D, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology. 2005;65:835-842.

498. Wolfe CD, Tilling K, Beech R, Rudd AG. Variations in case fatality and dependency from stroke in western and central Europe. The European BIOMED Study of Stroke Care Group. Stroke. 1999;30(2):350-6.

499. Counsell C, Dennis M, McDowall M, Warlow C. Predicting outcome after acute and subacute stroke: development and validation of new prognostic models. Stroke. 2002;33:1041-47.

500. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure- lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41.

501. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Longterm survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24(6):796-800.

502. Purroy F, Montaner J, Delgado Martínez P, Arenillas Lara JF, Molina CA, Santamarina E, et al. Utilidad de la realización de un estudio ultrasonográfico precoz en el pronóstico a corto plazo de los pacientes con un ataque isquémico transitorio. Med Clin (Barc). 2006;126:647-50.

503. Purroy F, Molina CA, Montaner J, Álvarez Sabín J. Absence of usefulness of abcd score in the early risk of stroke of transient ischemic attack patients. Stroke. 2007;38:855-856(a).

504. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284(22):2901-6.

505. Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JN, Warlow CP, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005;366(9479):29-36.

506. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283-92.

507. Bray JE, Coughlan K, Bladin C. Can the ABCD Score be dichotomised to identify high-risk patients with transient ischaemic attack in the emergency department? Emerg Med J. 2007;24(2):92-5.

508. Koton S, Rothwell PM. Performance of the ABCD and ABCD2 scores inTIA patients with carotid stenosis and atrial fibrillation. Cerebrovasc Dis. 2007;24(2-3):231-5.

509. Tsivgoulis G, Spengos K, Manta P, Karandreas N, Zambelis T, Zakopoulos N, et al. Validation of the ABCD score in identifying individuals at high early risk of stroke after a transient ischemic attack: a hospital-based case series study. Stroke. 2006;37(12):2892-7.

510. Cucchiara BL, Messe SR, Taylor RA, Pacelli J, Maus D, Shah Q, et al. Is the ABCD score useful for risk stratification of patients with acute transient ischemic attack? Stroke. 2006;37(7):1710-4.

511. Álvarez Sabín J, Quintana Luque M, Rodríguez M, Arboix A, Ramírez-Moreno J, Fuentes B. Validation of the Essen risk scale and its adaptation to the Spanish population. Modified Essen risk scale. Neurologia. 2008; [Epub ahead of print] Spanish.

512. Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Álvarez-Sabín J. Patterns and predictors of early risk of recurrence following transient ischemic attack regarding etiological subtypes. Stroke. 2007;38:3225-9(b).

513. Abilleira S, Ribera A, Sánchez E, Roquer J, Duarte E, Tresserras R, et al. La Atención Hospitalaria al Paciente con Ictus en Cataluña. Resultados del "Primer Audit Clínic de l'Ictus. Catalunya, 2005/2006". Gaceta Sanitaria. 2008 (en prensa).

514. Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc. 2004;52:1151-6.

515. Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke. 2000;31:1833-7.

516. Rigler SK, Webb MJ, Patel AT, Lai SM, Duncan PW. Use of antihypertensive and antithrombotic medications after stroke in communitybased care. Ann Pharmacother. 2001;35:811-6.

517. Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CD. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke. 2000;31:469-75.

518. Reims HM, Kjeldsen SE, Brady WE, Dahlof RB, Devereux RB, Julius S, et al. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrphy:The LIFE study. J Hum Hypertens. 2004;18:381-9.

519. Aguilar D, Skali H, Moye LA, Lewis EF, Gaziano JM, Rutheford JD, et al. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. J Am Coll Cardiol. 2004;43:2015-21.

520. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation. 1997; 96:3243-7.

521. Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2007 [Consultado el 17 de Marzo de 2008]. SIGN Publication No 97. Disponible en: http://www.sign.ac.uk/pdf/sign97.pdf Abre nueva ventana

522. Iso H, Date C, Yamamoto A, Toyoshima H, Watanabe Y, Kikuchi S, Koizumi A, Wada Y, Kondo T, Inaba Y, Tamakoshi A; JACC Study Group. Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol. 2005;161:170-9.

523. Myint PK, Welch AA, Bingham SA, Luben RN, Wareham NJ, Day NE, Khaw KT. Smoking predicts long-term mortality in stroke: The European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study. Prev Med. 2006;42:128-31.

524. Duncan P, Studenski S, Richards L, Gollub S, Lai SM, Reker D, et al. Randomized clinical trial of therapeutic exercise in subacute stroke. Stroke. 2003;34:2173-80.

525. Pla Director de la Malaltia Vascular Cerebral, coordinació. Guia de pràctica clínica de l'ictus. Actualització: gener 2007. Barcelona: Agència d'Avaluació de Tecnologia i Recerca Mèdiques. Departament de Salut. Generalitat de Catalunya; 2007.

526. Dey DK, Rothenberg E, Sundh V, Bosaeus I, Steen B. Waist circumference, body mass index, and risk for stroke in older people: a 15 year longitudinal population study of 70-year-olds. J Am Geriatr Soc. 2002 Sep;50(9):1510-8.

527. Gil-Núñez AC, Vivancos-Mora J. Blood pressure as a risk factor for stroke and the impact of antihypertensive treatment. Cerebrovasc Dis. 2005;20(suppl 2):40-52.

528. Rothwell PM, Howard SC, Spence JD; Carotid Endarterectomy Trialists’ Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003;34(11):2583-90.

529. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline fromthe AmericanHeart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5);1655-1711.

530. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34(11):2741-8.

531. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity andMortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 Jun;36(6):1218-26.

532. Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Setaro JF, et al. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology. 2004;63:208-213.

533. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-8.

534. Mancia G, DeBacker G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J. 2007; 28(12):1462-536.

535. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conthe P, et al:Comité Español Interdisciplinario para la Prevención Cardiovascular. Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention. Neurologia. 2004;19:438-9.

536. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(2):577-617.

537. Leys D, Kwiecinsky H, Bogousslavsky J, Bath P, Brainin M, Diener HC, et al; for the EUSI Executive Committee and the EUSI Writing Committee. Prevention. Cerebrovasc Dis. 2004;17(suppl 2):15-29.

538. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici H, Rudolf AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med. 2006;355:549-59.

539. Vergouwen M, Haan RJ, Vermeulen M, Roos Y. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39:497-502.

540. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 1;48(3):438-45.

541. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008 Feb 26;178(5):576-84.

542. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for Secondary Prevention in Elderly Patients: A Hierarchical Bayesian Meta-Analysis. J Am Coll Cardiol. 2008;51:37-45.

543. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006 Oct 3;145(7):520-30.

544. Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2007 [Consultado el 17 Marzo 2008]. SIGN Publication No 97. Disponible en: http://www.sign.ac.uk/pdf/sign97.pdf Abre nueva ventana

545. San Vicente Blanco R, Pérez Irazusta I, Ibarra Amarica J, Berraondo Zabalegui I, Uribe Oyarbide F, Urraca García de Madinabeitia J, et al. Guía de Práctica Clínica sobre el manejo de los lípidos como factor de riesgo cardiovascular. Osakidetza. GPC 2008/1. Vitoria-Gasteiz.

546. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2006;113(1):5-14.

547. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-49.

548. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576-84.

549. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, et al. Warfarin- Aspirin Recurrent Stroke Study Group: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-51.

550. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565-75.

551. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6(9):830-8.

552. Vitatops Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine- lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13(2):120-6.

553. B-Vitamin Treatmen Trialists’ Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151(2):282-7.

554. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and inuence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ. 1992;305:1460-5.

555. Bogousslavsky J, Hachinski VC, Boughner DR, Fox AJ, Vinuela F, Barnett HJ. Cardiac lesions and arterial lesions in carotid transient ischemic attacks. Archives of Neurology. 1986;43:223-8.

556. Harrison MJG, Marshall J. Atrial fibrillation, TIAs and completed stroke. Stroke. 1984;15:441-2.

557. Koudstaal PJ, van Gijn J, Klootwijk APJ, van der Meche FG, Kappelle LJ, et al. Holter monitoring in patients with transient and focal ischemic attacks of the brain. Stroke. 1986;17:192-5.

558. Whisnant JP, Brown RD, Petty GW, O'Fallon WM, Sicks JD, Wiebers DO. Comparison of population-based models of risk factors for TIA and ischemic stroke. Neurology. 1999;53:532-6.

559. Cerebral Embolism Task Force. Cardiogenic brain embolism. Archives of Neurology. 1986;43:71-84.

561. Saxena R (a), Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews. 2004, Issue 2. Art. No.: CD000185.

562. Saxena R (b), Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database of Systematic Reviews. 2004, Issue 4. Art. No.: CD000187.

563. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-62.

564. Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet. 1996;348:633-8.

565. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. ESC Committee for Practice guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230-68

566. Grunkemeier GL, Li HH, Naftel DC, Starr A, Rahimtoola SH. Long-term performance of heart valve prostheses. Curr Probl Cardiol. 2000;25:73-154.

567. Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986;112:1039-43.

568. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102:426S-33S.

569. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218-22.

570. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279:1273-7.

571. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc. 1999;74:862-9.

572. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a metaanalysis of case-control studies. Neurology. 2000;55:1172-9.

573. Mattioli AV, Aquilina M, Oldani A, Longhini C, Mattioli G. Atrial septal aneurysm as a cardioembolic source in adult patients with stroke and normal carotid arteries. A multicentre study. Eur Heart J. 2001;22:261-8.

574. Messe SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G, et al. Practice Parameter:Recurrent stroke with patent foramen ovale and atrial septal aneurysm. Neurology. 2004;62:1042-50.

575. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-6.

576. De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000;31:2407-13.

577. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation. 2002;105:2625-31.

578. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter Closure versus Medical Therapy of Patent Foramen Ovale and Presumed Paradoxical Thromboemboli: A Systematic Review. Ann Intern Med. 2003;139(9):753.

579. González-Fajardo JA, Cenizo-Revuelta N, San José-Barrachina I, del Río-Solá ML, Gutiérrez-Alonso VM, Vaquero-Puerta C. Relación entre morfología de la placa y la clínica. Angiología. 2004;56:S97-S108.

580. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with highgrade carotid stenosis. N Engl J Med. 1991;325:445- 53.

581. European Carotid Surgery Trialists’ Collaborative Group. MRC European Carotid SurgeryTrial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet. 1991;337:1235-43.

582. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis: Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA. 1991;266:3289-94.

583. Cina CS, Clase CM, Haynes RB. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database of Systematic Reviews. 1999, Issue 3. Art.No.: CD001081.

584. Ballotta E, Da Giau G, Baracchini C, Abbruzzese E, Saladini M, Meneghetti G. Early versus delayed carotid endarterectomy after a nondisabling ischemic stroke: a prospective randomized study. Surgery. 2002;131(3):287-93.

585. Welsh S, Mead G, Chant H, Picton A, O'Neill PA, McCollum CN. Early Carotid Surgery in Acute Stroke: A Multicentre Randomised Pilot Study. Cerebrovascular Diseases. 2004;18(3):200-5.

586. CAPRIE steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in people at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-39.

587. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-20.

588. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients:Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321:501-7.

589. Matias-Guiu J, Ferro JM, Álvarez-Sabín J, Torres F, Jiménez MD, Lago A, et al. Comparison of triusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind,multicenter trial. Stroke. 2003;34(4):840-8.

590. Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, et al. Triusal vs aspirin for prevention of cerebral infarction. A randomized stroke study. Neurology. 2004;62:1073-80.

591. Costa J, Ferro JM, Matías-Guiu J, Álvarez-Sabín J, Torres F. Triusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews. 2005, Issue 3. Art. No.: CD004296.

592. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke: A combined analisys of 40.000 randomized patients from the chinese acute stroke trial and the international stroke trial. Stroke. 2000;31:1240-9.

593. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipiridamole versus aspirin for prevention of vascular events after stroke or TIA. Stroke. 2008;39:1358-63.

594. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Systematic Reviews. 2006, Issue 2. Art No.: CD001820.

595. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665-73.

596. Algra A. ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurology. 2007;6(2):115-24.

597. Bhatt DL, Fox KA, Hacke W, Berger PB, Boden WE, Cacoub P, CHARISMA Investigators, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.

598. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-7.

599. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982-8.

600. Diener HC, Sacco R, Yusuf S, Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extendedrelease dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23(5-6):368-80.

601. Algra A, De Schryver ELLM, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database of Systematic Reviews. 2006, Issue 3. Art. No.: CD001342.

602. De Bruijn SFTM, de Haan RJ, Stam J, for the Cerebral Venous Sinus Thrombosis Study Group. Clinical features and prognostic factors of cerebral venous and sinus thrombosis in a prospective series of 59 patients. J Neurol Neurosurg Psychiatry. 2001;70:105-8.

603. De Veber G, Andrew M, Adams C, for the Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children.New Eng JMed. 2001;345:417-23.

604. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurology. 2007;6:162-70.

605. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, for the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis. Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-70.

606. De Bruijn SFTM, Stam J. for the Cerebral Venous Sinus Thrombosis Study Group. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular- weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484-88.

607. Einhäupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597-600. 608. Nagaraja D, Rao BSS, Taly AB, Subhash MN. Randomized controlled trial of heparinin puerperal cerebral venous/sinus thrombosis. Nimhans J. 1995;13:111-5.

608. Nagaraja D, Rao BSS, Taly AB, Subhash MN. Randomized controlled trial of heparinin puerperal cerebral venuos/sinus thrombosis. Nimhans J. 1995;13:111-5.

609. Stam J, de Bruijn SFTM, De Veber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database of Systematic Reviews. 2002, Issue 4. Art. No.: CD002005.

610. Canhao P, Falcao F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis. 2003;15:159-66.

611. Ciccone A, Canhao P, Falcao F, Ferro JM, Sterzi R. Thrombolysis for cerebral vein and dural sinus thrombosis. Stroke. 2004;35:2428.

612. Ferro JM, Canhão P, Bousser M-G, Barinagarrementeria F. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36:1927-32.

613. Einhäupl K, Bousser MG, de Bruijn SF, Ferro JM, Martinelli I, Masuhr F, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2006;13(6):553-9.

614. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, HertzbergVS, Frankel MR, et al. For the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-16.

615. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. A metaanalysis of randomized controlled trials. JAMA. 1998;280:1930-5.

616. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-93.

617. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-52.

618. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-26.

619. Berwaerts J, Webster J. Analysis of risk factors involved in oral-anticoagulant– related intracranial hemorrhages. Q J Med. 2000;93:513-521.

620. Ananthasubramaniam K, Beattie JN, Rosman HS, Jayam V, Borzak S. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major bleed? Chest. 2001;119:478-84.

621. Phan T, Koh M, Wijdicks E. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol. 2000;57:1710-3.

622. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34(7):1710-6.

623. Keir SL, Wardlaw JM, Sandercock PA, Chen Z. Antithrombotic therapy in patients with any form of intracranial haemorrhage: a systematic review of the available controlled studies. Cerebrovasc Dis. 2002;14(3-4):197-206.

624. Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1991; 54:466-7.

 

Última actualización: mayo 2009

Logo del Ministerio de Sanidad y Política Social Logo del Plan de Calidad del Sistema Nacional de SaludAgència d’Avaluació de Tecnologia i Recerca Mèdiques de Cataluña

 

Copyright | Ayuda | Mapa